Danaher(US:DHR)2025-04-22 15:10First Quarter 2025 Performance - Revenue decreased by 1.0% from Q1 2024, with core revenue being flat, acquisitions/divestitures contributing +0.5%, and foreign exchange (FX) impacting -1.5%[5] - Adjusted diluted net earnings per common share decreased by 2.1% from $1.92 in Q1 2024 to $1.88 in Q1 2025[5] - Adjusted operating profit margin decreased by 50 BPS, from 30.1% in Q1 2024 to 29.6% in Q1 2025[5] Segment Performance - Biotechnology revenue increased by 6.0%, with core growth of +7.0% and FX impacting -1.0%, resulting in revenue of $1.612 billion in Q1 2025 compared to $1.524 billion in Q1 2024; adjusted operating profit margin increased by 590 BPS, from 35.6% to 41.5%[8] - Life Sciences revenue decreased by 3.5%, with core decline of -4.0%, acquisitions contributing +2.0%, and FX impacting -1.5%, resulting in revenue of $1.680 billion in Q1 2025 compared to $1.745 billion in Q1 2024; adjusted operating profit margin decreased by 220 BPS, from 23.0% to 20.8%[10] - Diagnostics revenue decreased by 3.0%, with core decline of -1.5%, divestitures impacting -0.5%, and FX impacting -1.0%, resulting in revenue of $2.449 billion in Q1 2025 compared to $2.527 billion in Q1 2024; adjusted operating profit margin decreased by 340 BPS, from 34.7% to 31.3%[12] Financial Position - Net cash provided by operating activities decreased from $1.739 billion to $1.299 billion, a ~ (25.5)% change year-over-year[42] - Free cash flow decreased from $1.448 billion to $1.060 billion, a ~ (27.0)% change year-over-year[42] Guidance - The company forecasts low-single digit core sales growth for the three-month period ending June 27, 2025, and ~3.0% for the year ending December 31, 2025[23] - Adjusted operating profit margin is forecasted to be ~25.5% for the three-month period ending June 27, 2025[23] - Adjusted diluted net earnings per common share are forecasted to be $7.60 - $7.75 for the year ending December 31, 2025[23]